Recently, inflammation scores such as the platelet‐to‐lymphocyte ratio (PLR), neutrophil‐to‐lymphocyte ratio (NLR), and systemic immune‐inflammation index (SII), along with conventional serological tumor biomarkers like carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 72‐4, CA125, CA19‐9, and alpha‐fetoprotein (AFP), have been evaluated as non‐invasive biomarkers for immunotherapy response [15, 16, 17]. The gene discussed is AFP; the disease is neoplasm.